Microtesla magnetic therapy for cognitive impairment in long COVID: a randomized pilot study

Clicks: 14
ID: 330030
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #155 of 194 articles by views in Brain communications

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 194 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Cognitive impairment is common in post-acute sequelae of severe acute respiratory syndrome coronavirus 2 infection (long COVID) and substantially affects function and quality of life. Evidence suggests that sustained neuroinflammation, cerebrovascular dysfunction, and mitochondrial impairment contribute to cognitive symptoms. Microtesla Magnetic Therapy (MMT) is a transcranial, low-amplitude radiofrequency magnetic field intervention that has shown anti-inflammatory and neuroprotective effects in preclinical models, suggesting potential value in long COVID and other neurological disorders. This is the first randomized controlled trial of MMT for long COVID cognitive impairment. We evaluated the feasibility (primary) and safety (secondary) of at-home MMT in individuals with objective cognitive impairment from long COVID. Thirty participants were randomized 2:1 to active or sham MMT and self-administered 15-minute treatments at home twice weekly for 4 weeks, with remote monitoring, using a head-worn device delivering a nonthermal radiofrequency magnetic field to the whole brain. Feasibility was defined as completing at least 80% of prescribed treatments and all study visits. Safety was assessed by adverse events. Cognitive function and self-reported mood and quality of life were exploratory outcomes assessed at baseline, Week 4 (post-treatment), and Week 8 (follow-up). Feasibility was high: all participants who completed the study adhered to 100% of treatments, and usability ratings were strong. No device-related adverse events occurred. Compared with sham, active MMT participants showed significantly greater improvement from baseline to Week 8 in Wechsler Adult Intelligence Scale Digit Span Sequencing (p = 0.026), Hopkins Verbal Learning Test-Revised Total Recall (p = 0.044), and Delis-Kaplan Executive Function System Color Naming (p = 0.049). Other measures of attention, processing speed, and executive function did not differ significantly between groups. Emotional well-being on the 36-Item Short Form Survey improved significantly more with active MMT at Week 8 (p = 0.017). Depression and anxiety decreased in both groups; the anxiety reduction was greater with active treatment in the linear mixed-effects model (week × treatment interaction, p = 0.038) but not in the between-group change score comparison (p = 0.057). At-home MMT was feasible, safe, and well tolerated in individuals with cognitive impairment from long COVID. These preliminary, exploratory findings showed nominally significant between-group differences favoring active treatment on selected cognitive measures and emotional well-being and require confirmation in larger, adequately powered trials.
Reference Key
openalex_W7214579763 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Alexandra Canori, Eric Watson, Devanshi Patel, Arianna Fiorentino, Christopher Santiago, David Maltz, Blake Gurfein, David Putrino, Jacqueline Becker
Are you one of these authors? Claim your profile
Journal Brain communications
Year 2026
DOI
10.1093/braincomms/fcag364
URL
https://doi.org/10.1093/braincomms/fcag364
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.